Alcami began work on Flexion Therapeutics's ZILRETTA in the fall of 2014 and today announced that it will further support commercial supply of the product, which is approved for the treatment of OA-related knee pain.
Covance has acquired Sciformix in a deal that augments the CRO’s pharmacovigilance capabilities for post-approval safety solutions and expands its global footprint.
Following on from the success of last year's survey, Outsourcing-Pharma is running another 'state of the industry' survey to gauge views about the current state of the pharmaceutical contract services industry.
Marken has expanded its cryogenic services to support demand driven by an increasing amount of global cell and gene therapy clinical trials – a market projected to reach $363m by 2022.
The US FDA has issued a policy that provides the proper definition of an outsourcing facility in an effort to ensure compounded drugs are made under appropriate quality standards.
The UK-based CRO RxCelerate continues to expand with its recent acquisition of The Cambridge Partnership for £1.45m ($1.96m) as it aims to carry out its vision of supporting virtual biotech companies.
The acquisition of Analytica Laser adds real-world effectiveness prediction and value assessment to Certara's service portfolio – as it aims to “tackle trial to real-world value translation,” says exec.
Regulations are changing across the globe as patients, the scientific community, and other stakeholders call for increased clinical trial data transparency.
With less than a year until the full implications of Brexit set in, Parexel consultants urge the industry to not wait – assess potential risks, such as to the clinical supply chain, and take actions to mitigate them.
In this month’s roundup, new CEO’s at Center Point Clinical Services and Clinipace Worldwide, and an equity investment in Dotmatics, which has named a new CFO.
The US Patent and Trademark Office has granted a notice of allowance for ‘shelf life’ timer technology used to protect time-sensitive biologic materials in transit.
Ubiquitous M&A activity in the pharmaceutical industry raises several concerns – with many scholars arguing that 70 to 80% of acquisitions end up destroying value.
